STOCK TITAN

ProQR Therapeutics N.V. - $PRQR STOCK NEWS

Welcome to our dedicated page for ProQR Therapeutics N.V. news (Ticker: $PRQR), a resource for investors and traders seeking the latest updates and insights on ProQR Therapeutics N.V. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProQR Therapeutics N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProQR Therapeutics N.V.'s position in the market.

Rhea-AI Summary
ProQR Therapeutics NV. (Nasdaq: PRQR) reported €120.6M in cash and cash equivalents as of September 30, 2023, providing runway into mid-2026. The company continues to advance AX-0810 for cholestatic diseases and AX-1412 for cardiovascular risk, with upcoming pipeline program data releases. ProQR also announced strengthening of its IP position with new patents in the US and successful defense against opposition in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.66%
Tags
-
Rhea-AI Summary
ProQR Therapeutics has strengthened its intellectual property estate with the issuance of a new patent in the United States and successfully defended against an opposition to its IP in Japan. The new patent expands the protection of RNA editing using oligonucleotides to recruit endogenous ADAR, further solidifying ProQR's leading IP position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
-
Rhea-AI Summary
ProQR Therapeutics NV. (Nasdaq: PRQR) announced that CEO Daniel A. de Boer will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
Rhea-AI Summary
ProQR Therapeutics terminates agreement to divest ophthalmic assets to Laboratoires Théa due to key personnel not proceeding with employment at Théa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
-
Rhea-AI Summary
ProQR Therapeutics NV. to participate in HC Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
ProQR Therapeutics N.V.

Nasdaq:PRQR

PRQR Rankings

PRQR Stock Data

155.97M
57.49M
18.87%
40.33%
0.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Leiden

About PRQR

proqr therapeutics is a leiden, nl based biotech company focused on developments of drugs to treat genetic disorders. based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. founded by industry icons and based on ground breaking science we strive to make a meaningful impact. check out our website for vacancies: www.proqr.com